Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Thoracic Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Neoplasms, Nerve Tissue 1Neoplasms, Germ Cell and Embryonal 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Lung Neoplasms 1Lung Diseases 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Medullary 1Carcinoma, Bronchogenic 1Carcinoma 1Bronchial Diseases 1Adenocarcinoma 1

Interventions

Pemetrexed 4Carboplatin 4pembrolizumab 3Gemcitabine 2Erlotinib Hydrochloride 2Cisplatin 2pralsetinib 1patritumab 1camrelizumab 1Vinorelbine 1Paclitaxel 1Gefitinib 1Docetaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Respiratory Tract Diseases × pralsetinib × Clear all
NCT04222972 2026-03-05

AcceleRET-Lung

Hoffmann-La Roche

Phase 3 Terminated
223 enrolled 18 charts
Head & NeckThoracic

Adenocarcinoma, Bronchial Diseases, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡